The American College of Cardiology is developing a program with support from founding sponsor AstraZeneca to provide personalized services to heart disease patients and help avoid a quick return to the hospital.
Nearly one in five patients hospitalized with heart attack and one in four patients hospitalized with heart failure are readmitted within 30 days of discharge, often for conditions seemingly unrelated to the original diagnosis. Readmissions can be related to issues like stresses within the hospital, fragility on discharge, lack of understanding of discharge instructions and inability to carry out discharge instructions.
The $10 million sponsorship from AstraZeneca will allow the ACC to create a Patient Navigator Program that will support a team of caregivers to help patients overcome challenges during their hospital stay and in the weeks following discharge when they are most vulnerable. The ultimate goal will be to create a program that supports a culture of patient-centered care that can be implemented in other hospitals.
"The ACC Patient Navigator Program will serve as a test for innovative, patient-centered solutions to address issues that impact patient readmissions," said ACC President John G. Harold, MD, MACC. "A team of caregivers focused on the patients' ongoing needs can make the patient's hospitalization less stressful and the post-discharge period more supportive. The goal is for patients to make a seamless transition from the hospital to the home."
The ACC will recruit 35 hospitals that already participate in the ACC's National Cardiovascular Data Registry and the Hospital to Home Initiative. The program will utilize and expand upon improvement strategies, toolkits and other best practices learned from communities within these programs in more than 1,500 hospitals in the U.S.
"Supporting the development of the ACC Patient Navigator Program allows AstraZeneca to make a difference for patients and caregivers while helping support a program that we hope will have a long-term impact on the quality of care patients receive as they transition from hospital to home following a heart attack," said Paul Hudson, Executive Vice President, North America, AstraZeneca.
To view the announcement of the ACC Patient Navigator Program, visit http://www.youtube.com/watch?v=GYzea7GncvI.
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
The NCDR is the preeminent cardiovascular data repository in the United States. Through the analysis and benchmarking of patient risk factors, procedures, devices and clinical outcomes, the NCDR's growing suite of registries provides evidence-based quality improvement solutions for cardiologists and other medical professionals who are committed to measurement, improvement and excellence in cardiovascular care. More information about the NCDR is available at http://www.ncdr.com.
The mission of the American College of Cardiology is to transform cardiovascular care and improve heart health. The College is a 43,000-member medical society comprised of physicians, surgeons, nurses, physician assistants, pharmacists and practice managers. The College is a leader in the formulation of health policy, standards and guidelines. The ACC provides professional education, operates national registries to measure and improve quality of care, disseminates cardiovascular research, and bestows credentials upon cardiovascular specialists who meet stringent qualifications. For more information, visit cardiosource.org/ACC.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.